Correlation between Insulin Resistance with Soluble CD40 Ligand and Plasminogen Activator Inhibitor-1 Plasma in Pre-diabetic Patients
DOI:
https://doi.org/10.3889/oamjms.2022.8202Keywords:
Insulin resistance, HOMA IR, sCD40 ligand, PAI-1, Pre-diabetesAbstract
BACKGROUND: The main condition of pre-diabetes is insulin resistance that can lead to a prothrombotic state.
AIM: This study aims to correlate insulin resistance with soluble CD40 ligand (sCD40L) and plasminogen activator inhibitor-1 (PAI-1) plasma in pre-diabetic patients.
METHODS: This study is an analytic observational study with a cross-sectional approach. HOMA-IR assessed insulin resistance, and prothrombotic factors were assessed by PAI-1 and soluble CD40L. PAI-1 and sCD40L were examined by ELISA. These indicators were assessed on 30 pre-diabetic patients.
RESULTS: Thirty subjects included in this study with a mean age of 31.47 (5.03) years old, consist of 19 (63%) men and 11 (37%) women. The mean HOMA-IR was 3.69 (1.12), PAI-1 was 10.25 (3.72) ng/mL, and the PAI-1 levels were increased (>8.4 ng/mL) in 70% of the subjects. The mean of sCD40L levels was 4495.7 (1136.3) pg/ml, and sCD40L levels were increased (>4000 pg/ml) in 63% of subject. There was a significant correlation between HOMA-IR levels and sCD40L (r = 0.636, p < 0.05) and between of HOMA-IR and PAI-1 (r = 0.742, p < 0.05). Moderate correlation was found between sCD40L levels and plasma PAI-1 (r = 0.592, p < 0.05) in pre-diabetic patient. The correlation between three variables was HOMA-IR had a significant effect on PAI-1 levels through sCD40L (t = 2.010, p < 0.05, structure loading factor = 0.286).
CONCLUSION: Insulin resistance has a strong and significant correlation with sCD40L and PAI-1 levels in pre-diabetic patients.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
IDF Diabetes Atlas. International Diabetes Federation (IDF). 9th ed. Brussels, Belgium: IDF; 2019.
Perkeni, Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia; 2019.
Decroli E, Kam A, Dillasamola D. The percentage of depressive symptoms in patients with Type 2 Diabetes Mellitus in M Djamil General Hospital Padang, Indonesia. J Res Pharm. 2019;23(2):292-7. DOI: https://doi.org/10.12991/jrp.2019.136
Decroli E, Efendi YP, Kam A, Manaf A, Syahbuddin S. Description of Insulin Resistance and Beta Cell Pancreas Dysfunction in Prediabetic Patients, ICoMHER; 2018. https://doi.org/10.4108/eai.13-11-2018.2283632 DOI: https://doi.org/10.4108/eai.13-11-2018.2283632
Ghani M, Ralph A. Pathophysiology of prediabetes. Curr Diab Rep. 2009;9(3):193-9. DOI: https://doi.org/10.1007/s11892-009-0032-7
Decroli E, Manaf A, Syahbuddin S, Waspadji S, Dillasamola D. The role of survivin and raf-1 kinase against enhancement of pancreatic beta-cell apoptosis in patients with Type 2 diabetes mellitus. Asian J Pharm Clin Res. 2018;11(11):344-7. https://doi.org/10.22159/ajpcr.2018.v11i11.27671 DOI: https://doi.org/10.22159/ajpcr.2018.v11i11.27671
Decroli E, Manaf A, Syahbuddin S, Syafrita Y, Dillasamola D. The correlation between malondialdehyde and nerve growth factor serum level with diabetic peripheral neuropathy score. Open Access Maced J Med Sci. 2019;7(1):103-6. https://doi.org/10.3889/oamjms.2019.029 PMid:30740170 DOI: https://doi.org/10.3889/oamjms.2019.029
Kleinherenbrinka W, Oseib E, den Hertogc HM, Zandbergen AA. Prediabetes and macrovascular disease: Review of the association, influence on outcome and effect of treatment. Eur J Intern Med. 2018;55:6-11. https://doi.org/10.1016/j.ejim.2018.07.00 PMid:30007840 DOI: https://doi.org/10.1016/j.ejim.2018.07.001
Beulens JW, Rutters F, Ryden L, Schnell O, Mellbin L, Hart HE, et al. Risk and management of pre-diabetes. Eur J Prev Cardiol. 2019;26(2S):47-54. https://doi.org/10.1177/2047487319880041 PMid:31766914 DOI: https://doi.org/10.1177/2047487319880041
Ciccone MM, Scicchitano P, Cameli M, Cecere A, Cortese F, Dentamaro I, et al. Endothelial function in pre-diabetes, diabetes and diabetic cardiomyopathy: A review. J Diabetes Metab. 2014;5(4):1-10.
Kacker S, Saboo N, Sorout J. Prediabetes: Pathogenesis and adverse outcomes. Int J Med Res Prof. 2018;4(2):1-6.
Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med. 2016;241:1323-31. DOI: https://doi.org/10.1177/1535370216654227
Michel NA, Zirlik A, Wolf D. CD40L and its receptors in atherothrombosis-an update, front. Cardiovasc Med. 2017;4:1-18.
Santilli F, Simeone P, Liani R. The Role of Platelets in Diabetes Mellitus. Department of Medicine and Aging and Haemostasis and Thrombosis Unit. Amsterdam, Netherlands: Elsevier; 2019. p. 469-503. DOI: https://doi.org/10.1016/B978-0-12-813456-6.00027-8
Pusuroglu H, Akgul O, Erturk M, Uyarel H, Bulut U, Akkaya E, et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis. 2014;25(7):558-64. DOI: https://doi.org/10.1097/MCA.0000000000000142
Li J, Wang Y, Lin J, Wang D, Wang A, Zhao X, et al. Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke. 2015;46(7):1990-2. DOI: https://doi.org/10.1161/STROKEAHA.115.008685
Tony AA, Tony EA, Mohammed WS, Kholef EF. Evaluation of plasma levels of neopterin and sCD40L in patients with acute ischemic stroke in upper Egypt: Can they surrogate the severity and functional outcome? Neuropsychiatr Dis Treatment. 2019;15:575-86. https://doi.org/10.2147/NDT.S177726 PMid:30863079 DOI: https://doi.org/10.2147/NDT.S177726
Benyamin AF, Minhajat R, Bayu D, Saleh S, Harjianti T. Association between PAI-1 activity levels and t-PA antigen with glycemic status in prediabetic population. Acta Med Indones. 2016;48(3):200-6. PMid:27840354
Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: A therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol. 2017;16(1):34. https://doi.org/10.1186/s12933-017-0515-9 PMid:28279217 DOI: https://doi.org/10.1186/s12933-017-0515-9
Rajput R, Rajput M, Mishra S, Ahlawat P. Prevalence of metabolic syndrome in prediabetes. Metab Syndr Relat Disord. 2019;17(8):406-10. https://doi.org/10.1089/met.2019.0010 PMid:31305207 DOI: https://doi.org/10.1089/met.2019.0010
Salazar M, Horacio A, Walter G, Marcelo A, Carlos E, Betty C, et al. Insulin resistance: The linchpin between prediabetes and cardiovascular disease. Diab Vasc Dis Res. 2016;13(2):157-63. https://doi.org/10.1177/1479164115610057 PMid:26802220 DOI: https://doi.org/10.1177/1479164115610057
Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016. JAMA Pediatr. 2020;174(2):e194498. https://doi.org/10.1001/jamapediatrics.2019.4498 PMid:31790544 DOI: https://doi.org/10.1001/jamapediatrics.2019.4498
Mandob DE, Sabine P. Metabolic syndrome prevalence among prediabetic and normoglucotolerant women. J Diabetes Metab. 2016;7:1-5. DOI: https://doi.org/10.4172/2155-6156.1000705
Barbu E, Popescu MR, Popescu AC, Balanescu SM. Phenotyping the prediabetic population-a closer look at intermediate glucose status and cardiovascular disease. Int J Mol Sci. 2021;22(13):6864. https://doi.org/10.3390/ijms22136864 PMid:34202289 DOI: https://doi.org/10.3390/ijms22136864
Gupta AK, Menon A, Brashear M, Johnson WD. Prediabetes: Prevalence, pathogenesis, and recognition of enhanced risk. In: Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Vol. 2. Amsterdam, Netherlands: Elsevier; 2018. p. 15-32. DOI: https://doi.org/10.1016/B978-0-12-812019-4.00002-7
Ahsan S, Ahmed SD, Jamali SN, Imran M, Haque MS, Qasim R. Frequency and risk of metabolic syndrome in prediabetics versus normal glucose tolerant subjects: A comparative study. J Pak Med Assoc. 2015;65(5):496-500. PMid:26028383
Gateva A, Assyov Y, Tsakova A, Kamenov Z. Soluble CD40L is associated with insulin resistance, but not with glucose tolerance in obese nondiabetic patients. Arch Physiol Biochem. 2016;122(3):161-5. https://doi.org/10.3109/13813455.2016.1160934 PMid:26934129 DOI: https://doi.org/10.3109/13813455.2016.1160934
Linna H, Suija K, Rajala U, Herzig KH, Karhu T, Jokelainen J. The association between impaired glucose tolerance and soluble CD40 ligand: A 15-year prospective cohort study. Aging Clin Exp Res. 2016;28(6):1243-9. https://doi.org/10.1007/s40520-015-0524-z PMid:26749117 DOI: https://doi.org/10.1007/s40520-015-0524-z
Michel NA, Zirlik A, Wolf D. CD40L and its receptors in atherothrombosis-an update. Front Cardiovasc Med. 2017;4:40. https://doi.org/10.3389/fcvm.2017.00040 PMid:28676852 DOI: https://doi.org/10.3389/fcvm.2017.00040
Yuan M, Fu H, Ren L, Wang H, Guo W. Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis. Cardiology. 2015;131(1):1-12. https://doi.org/10.1159/000374105 PMid:25825037 DOI: https://doi.org/10.1159/000374105
Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157-72. https://doi.org/10.1111/j.1365-2796.2007.01824.x PMid:17645584 DOI: https://doi.org/10.1111/j.1365-2796.2007.01824.x
Laryushina Y, Parakhina V, Turgunova L, Sheryazdanova D, Dosmagambetova S, Turmukhambetova A, et al. Association of plasminogen activator inhibitor-1 and cardiovascular events development in patients with prediabetes. Open Access Maced J Med Sci. 2021;9(B):726-33. DOI: https://doi.org/10.3889/oamjms.2021.6825
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Eva Decroli, Rudy Afriant, Alexander Kam, Upi Puspita (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
